Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Looking Into Reata Pharmaceuticals's Return On Capital Employed
 
Via Benzinga
Analyst Ratings for Reata Pharmaceuticals
 
Via Benzinga
Why Reata Pharmaceuticals Stock Is Soaring Today
Investors are cheering the company's third-quarter update. 
Via The Motley Fool
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
These two growth stocks might deliver enormous gains for shareholders this month. 
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals... 
Via Benzinga
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Planet Fitness To Surge Over 25%? Plus Morgan Stanley Cuts PT On This Stock By 50%
Raymond James raised the price target on Planet Fitness, Inc. (NYSE: PLNT) from $70 to $84. Raymond James analyst Joseph Altobello maintained a Strong Buy rating on the stock. Planet Fitness shares... 
Via Benzinga
DuPont, Expeditors International, Planet Fitness And Other Big Gainers From Tuesday
U.S. stocks closed higher on Tuesday, with the Dow Jones surging more than 300 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns. 
Via The Motley Fool
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Dow Dips 375 Points; S&P 500 Down Over 2%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 375 points on Friday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
Upgrades 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52. 
Via Benzinga
Why Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?
The FDA will not hold a meeting to review Reata Pharmaceuticals’ therapeutic for a rare disorder yet RETA stock soared. Here’s why. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Why Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session
Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 77.7% to $9.35. 
Via Benzinga
Nasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday. 
Via Benzinga
US Stocks Open Lower; Dow Drops Over 100 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Friday. 
Via Benzinga
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.